Abstract: Enhanced biologic grafts with packaging apparatuses, and methods of use are disclosed herein. An example apparatus can include a vessel comprising a port that is configured to allow a fluid to be introduced into the vessel and a membrane placed within the vessel. The membrane is lyophilized prior to placement into the vessel. The membrane is sealed within the vessel and the port can be used to introduce a fluid into the vessel to reconstitute the membrane while sealed inside the vessel.

Abstract: The present invention provides methods to assess the genetic safety of stem cells, whether endogenous embryonic stem cells, somatic or adult stem cells, or artificially induced stem cells from non-pluripotent cells, and their differentiated derivatives for use in human medicine, and the applications of modified stem cells to testing environmental or potential genetic or epigenetic modulators such as culture media formulations, substrates or scaffolds, additives, reagents, processes, and processing materials used to prepare stem cells for use.

Abstract: A method for using polyamine analogues containing bulky hydrophobic groups against antimicrobial agents is disclosed. The antimicrobial method works by the mechanical action of disrupting the protective outer member of a bacterial cell.

Abstract: This invention relates to methods and systems for generating a safe and effective oral smallpox vaccine for humans using a genetically defective strain of vaccinia virus to confer immunity following oral delivery of the vaccine. This invention is one that expands on current use of vaccinia virus propagation developed for gene therapy applications, and pharmaceuticals and nutraceuticals packaging and formulation technologies. The vaccine invention can be delivered as a live virus with the ability to express viral proteins but unable to achieve complete, lytic virus replication, or it may be derived from such a virus, contain additional immunogens, or be delivered as viral antigens. Furthermore, the invention establishes innovative methods for formulation and packaging and for preclinical testing of the vaccine invention for safety, efficacy and potency with the use of human intestinal and other test cells and diagnostic test systems and kits.

Abstract: This invention relates to methods and systems for generating a safe and effective oral smallpox vaccine for humans using a genetically defective strain of vaccinia virus to confer immunity following oral delivery of the vaccine. This invention is one that expands on current use of vaccinia virus propagation developed for gene therapy applications, and pharmaceuticals and nutraceuticals packaging and formualtion technologies. The vaccine invention can be delivered as a live virus with the ability to express viral proteins but unable to achieve complete, lytic virus replication, or it may be derived from such a virus, contain additional immunogens, or be delivered as viral antigens. Furthermore, the invention establishes innovative methods for formulation and packaging and for preclinical testing of the vaccine invention for safety, efficacy and potency with the use of human intestinal and other test cells and diagnostic test systems and kits.

Abstract: The invention is a formulation and method of use for a nutritional dietary supplement to prevent the side effects of cancer therapy and thus augment the efficacy of treatment. Cancer therapy refers to treatment with various formulations of chemicals (chemotherapy), or combined modality therapies that may include chemotherapy, radiation therapy, and/or surgery. The formulation of the nutritional supplement is highly enriched in .omega.3 fatty acids. The preparation and packaging of the nutritional supplement are done under reducing conditions such as in the presence of nitrogen, to avoid oxidation of the compound. The invention further describes the method of pre-treatment of tumor-bearing mammals with the nutritional supplement such that it precedes the initiation of, then is continued concomitant with, the therapy. The invention describes a way to protect normal organ function and reduce inflammation, as exemplified by the gastrointestinal tract, liver, and bone marrow upon chemotherapy treatment.

Abstract: Methods for the expansion of blood stem cells and their activation as dendritic cells in a scheme for adjuvant immune therapy of patients with cancer or other diseases. The utility of combining a trade secret formulation of INCELL's M3™ medium in the expansion and activation of immune system stem cells and differentiated cells, including dendritic cells, with subsequent immunoreactivity against tumor cell antigens is demonstrated. The patent also describes long-term culture and cryopreservation of cells that maintain their reactivity and functionality, suggesting their potential use as universal donor cells. Furthermore, it describes how a dendritic cell activation kit can be developed using the approaches and the cell and media tools described.